Recombinant Antibody to Programmed Cell Death Protein 1 (PD1) Canis familiaris; Canine (Dog) Protein, Antibody, Assaykit, Service

CD279; PDCD1; SLEB2; HPD1P

Add to Cart Distributors
Overview
Properties
  • SourceRecombinant monoclonal antibody preparation, Host 293F
  • Ig Isotype IgG, Clone Number n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelFITC
  • Immunogen n/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid, Concentration 1mg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Recombinant Antibody to Programmed Cell Death Protein 1 (PD1) Packages (Simulation)
  • Recombinant Antibody to Programmed Cell Death Protein 1 (PD1) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a mouse monoclonal antibody raised against PD1. It has been selected for its ability to recognize PD1 in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.pubmed:28545019
  • Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке:
  • АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1‑ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ …
  • Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor ActivityPubmed: 30699956
  • Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …Pubmed: 30807610
  • Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyPubmed: 32085544

Recommend products